{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:34:04Z","timestamp":1780914844280,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to explore the difference between <jats:sup>11<\/jats:sup>C-methyl-N-2\u03b2-carbomethoxy-3\u03b2-(4-fluorophenyl)-tropanel (<jats:sup>11<\/jats:sup>C-CFT) positron emission tomography (PET) imaging in the early-onset Parkinson\u2019s disease (EOPD) and late-onset Parkinson\u2019s disease (LOPD), and to analyze the correlation between <jats:sup>11<\/jats:sup>C-CFT PET imaging and disease duration, Hoehn &amp;amp; Yahr (H&amp;amp;Y) stage, motor symptoms, and non-motor symptoms in patients with idiopathic Parkinson\u2019s disease (PD), so as to explore its application value in assessing the severity of Parkinson\u2019s disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A total of 113 patients with idiopathic PD were included in this study. The patients were divided into EOPD and LOPD groups according to the age of 60\u2009years, of which 58 were early-onset and 55 were late-onset. All patients underwent <jats:sup>11<\/jats:sup>C-CFT PET imaging and manually sketched regions of interest (ROI) to delineate the caudate nucleus, anterior putamen, and posterior putamen ROI layer-by-layer, and the corresponding values were recorded. Clinical data [age of onset, disease duration, H&amp;amp;Y stage, total Unified Parkinson\u2019s Disease Rating Scale (UPDRS) score, UPDRS III score, tremor score, postural instability\/gait difficulty (PIGD) score, rigidity score, bradykinesia score, and Montreal Cognitive Assessment (MoCA) score] were collected from all patients. The differences in striatal <jats:sup>11<\/jats:sup>C-CFT uptake between patients with EOPD and LOPD were compared, and the correlation between striatal <jats:sup>11<\/jats:sup>C-CFT uptake and the clinical data of patients with idiopathic PD was evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The caudate nucleus <jats:sup>11<\/jats:sup>C-CFT uptake was higher in EOPD than in the LOPD group (<jats:italic>t<\/jats:italic>\u2009=\u20093.002, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). <jats:sup>11<\/jats:sup>C-CFT uptake in the caudate nucleus in patients with PD was negatively correlated with the age of onset, H&amp;amp;Y stage, disease duration, total UPDRS score, UPDRS III score, rigidity score, and bradykinesia score (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). The anterior and posterior putamen <jats:sup>11<\/jats:sup>C-CFT uptake was negatively correlated with H&amp;amp;Y stage, disease duration, total UPDRS score, UPDRS III score, PIGD score, rigidity score, and bradykinesia score (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:sup>11<\/jats:sup>C-CFT PET provides an objective molecular imaging basis for the difference in disease progression rates between patients with EOPD and LOPD. Secondly, <jats:sup>11<\/jats:sup>C-CFT PET can be used as an important objective indicator to assess disease severity and monitor disease progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1195577","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T16:26:46Z","timestamp":1688660806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics and influencing factors of 11C-CFT PET imaging in patients with early and late onset Parkinson\u2019s disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Fan","family":"Kangli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Hongguang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yinghua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Xiaoxiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Yuyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Lulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Zhihui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5603\/PJNNS.a2022.0014","article-title":"Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio may reflect differences in Pd and Msa-P neuroinflammation patterns","volume":"56","author":"Madetko","year":"2022","journal-title":"Neurol Neurochir Pol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e200132","DOI":"10.1212\/nxi.0000000000200132","article-title":"Inflammatory biomarkers in newly diagnosed patients with Parkinson disease and related neurodegenerative disorders","volume":"10","author":"Pedersen","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.bbadis.2009.10.013","article-title":"Inflammation in transgenic mouse models of neurodegenerative disorders","volume":"1802","author":"Schwab","year":"2010","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1016\/s1353-8020(13)70042-7","article-title":"Developments in neuroimaging: positron emission tomography","volume":"20","author":"Stoessl","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/mds.10592","article-title":"Role of dopamine transporter imaging in routine clinical practice","volume":"18","author":"Marshall","year":"2003","journal-title":"Mov Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/RLU.0b013e31824c5fae","article-title":"The influence of residual nor-Beta-Cft in C-11 Cft injection on the Parkinson disease diagnosis a C-11 Cft pet study","volume":"37","author":"Huang","year":"2012","journal-title":"Clin Nucl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"Mds clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/jpd-181517","article-title":"Revision of diagnosis in early parkinsonism with abnormal dopamine transporter imaging","volume":"9","author":"Massa","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.parkreldis.2014.02.013","article-title":"Comparing clinical features of young onset, middle onset and late onset Parkinson\u2019s disease","volume":"20","author":"Mehanna","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"Mds research criteria for prodromal Parkinson\u2019s disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (Mds-Updrs): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the Movement Disorder Society unified Parkinson\u2019s disease rating scale: comparison with the unified Parkinson\u2019s disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/jgs.15925","article-title":"The Montreal Cognitive Assessment, Moca: A Brief Screening Tool for Mild Cognitive Impairment","volume":"62","author":"Nasreddine","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"ref16","first-page":"652","article-title":"11c-Cft pet imaging to evaluate the distribution characteristics of dopamine transporters in the brain of patients with Parkinson\u2019s disease and multiple system atrophy P-type","volume":"25","author":"Zhang Weishan","year":"2017","journal-title":"Chinese Clin Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/syn.20653","article-title":"Visualizing vesicular dopamine dynamics in Parkinson\u2019s disease","volume":"63","author":"de la Fuente-Fernandez","year":"2009","journal-title":"Synapse"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1471-4159.2009.05904.x","article-title":"Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson\u2019s: an in vivo imaging study","volume":"109","author":"Sossi","year":"2009","journal-title":"J Neurochem"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1756286419851400","article-title":"Preserved caudate function in young-onset patients with Parkinson\u2019s disease: a dual-tracer pet imaging study","volume":"12","author":"Yang","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870130605","article-title":"Young-onset Parkinson\u2019s disease revisited--clinical features, natural history, and mortality","volume":"13","author":"Schrag","year":"1998","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jns.2014.01.015","article-title":"Comparison of dopamine transporter decline in a patient with Parkinson\u2019s disease and normal aging effect","volume":"339","author":"Ishibashi","year":"2014","journal-title":"J Neurol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1468-1331.2008.02514.x","article-title":"The effect of onset age on the clinical features of Parkinson\u2019s disease","volume":"16","author":"Wickremaratchi","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaneurol.2015.2397","article-title":"Basal ganglia circuits as targets for neuromodulation in Parkinson disease","volume":"72","author":"DeLong","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1212\/wnl.39.3.349","article-title":"Neurobehavioral changes associated with caudate lesions","volume":"39","author":"Mendez","year":"1989","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/syn.20708","article-title":"Dopamine transporter pet in normal aging: dopamine transporter decline and its possible role in preservation of motor function","volume":"64","author":"Troiano","year":"2010","journal-title":"Synapse"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.parkreldis.2015.10.017","article-title":"Onset-related subtypes of Parkinson\u2019s disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study","volume":"21","author":"Liu","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/2013.jamaneurol.45","article-title":"History, applications, and mechanisms of deep brain stimulation","volume":"70","author":"Miocinovic","year":"2013","journal-title":"JAMA Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::Aid-mds1014>3.0.Co;2-v","article-title":"Correlation of Parkinson\u2019s disease severity and duration with I-123-Fp-Cit Spect striatal uptake","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/mds.10482","article-title":"Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations","volume":"18","author":"Benamer","year":"2003","journal-title":"Mov Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1002\/mds.10579","article-title":"Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?","volume":"18","author":"Pirker","year":"2003","journal-title":"Mov Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/WNR.0b013e3282ef69f9","article-title":"I-23 Fp-Cit striatal binding in early Parkinson\u2019s disease patients with tremor vs. akinetic-rigid onset","volume":"18","author":"Isaias","year":"2007","journal-title":"Neuroreport"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00702-006-0518-2","article-title":"Striatal Fp-Cit uptake differs in the subtypes of early Parkinson\u2019s disease","volume":"114","author":"Spiegel","year":"2007","journal-title":"J Neural Transm"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ana.22361","article-title":"Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor","volume":"69","author":"Helmich","year":"2011","journal-title":"Ann Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1093\/brain\/aws023","article-title":"Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?","volume":"135","author":"Helmich","year":"2012","journal-title":"Brain"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.celrep.2021.109007","article-title":"Conveyance of cortical pacing for parkinsonian tremor-like hyperkinetic behavior by subthalamic dysrhythmia","volume":"35","author":"Huang","year":"2021","journal-title":"Cell Rep"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-7091-6360-3_1","article-title":"Post mortem studies in Parkinson\u2019s disease - is it possible to detect brain areas for specific symptoms?","volume":"56","author":"Jellinger","year":"1999","journal-title":"J Neural Transm Suppl"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"C-11-Pe2i and F-18-Dopa pet for assessing progression rate in Parkinson\u2019s: a longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Mov Disord"}],"updated-by":[{"DOI":"10.3389\/fneur.2023.1289550","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1195577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T09:05:34Z","timestamp":1695287134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1195577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":38,"alternative-id":["10.3389\/fneur.2023.1195577"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1195577","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fneur.2023.1289550","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"article-number":"1195577"}}